Podcasts about clinical trials

  • 2,423PODCASTS
  • 8,815EPISODES
  • 32mAVG DURATION
  • 2DAILY NEW EPISODES
  • Oct 27, 2025LATEST
clinical trials

POPULARITY

20172018201920202021202220232024

Categories



Best podcasts about clinical trials

Show all podcasts related to clinical trials

Latest podcast episodes about clinical trials

Intelligent Medicine
Intelligent Medicine Radio for October 25, Part 2: Cancer Incidence is Soaring

Intelligent Medicine

Play Episode Listen Later Oct 27, 2025 44:19


While we're making progress in TREATING cancer, worldwide cancer INCIDENCE is soaring, especially among young people; New guidelines for colon cancer screening urge earlier start at age 45; Rates of peanut allergy are declining as more parents follow revised advice to introduce nuts earlier to kids; What's with all the buzz about methylene blue? Legalization and stronger pot are creating an epidemic of ER visits for uncontrolled vomiting, debilitating abdominal pain; New smart toilet gives you a report card on your poop; When Zoloft doesn't work for anxiety.

The Incubator
#371 - [Journal Club Shorts] -

The Incubator

Play Episode Listen Later Oct 26, 2025 10:33


Send us a textNebulized nitroglycerin as an adjuvant drug in management of persistent pulmonary hypertension of newborns: a randomized controlled trial.Farag MM, Ghazal HAE, Abdel-Mohsen AM, Rezk MA.Eur J Pediatr. 2025 Sep 1;184(9):586. doi: 10.1007/s00431-025-06381-5.PMID: 40888971 Free PMC article. Clinical Trial.Support the showAs always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!

Hashtag Trending
Project Synapse: AI in Veterinary Medicine with Dr. Christopher Pinard

Hashtag Trending

Play Episode Listen Later Oct 25, 2025 70:06 Transcription Available


In this episode of Project Synapse, we explore the innovative use of AI in veterinary oncology with Dr. Christopher Pinard. Dr. Pinard, a veterinary oncologist, discusses his journey from coding HTML in grade school to developing AI-driven solutions for cancer in pets. He shares insights on the challenges and opportunities within veterinary medicine, the impact of AI on clinical efficiency, and the future of personalized medicine for pets. We also delve into issues like regulatory challenges, the importance of context in AI models, and the potential of federated learning. If you're interested in the intersection of AI and veterinary medicine, this episode is a must-watch! 00:00 Introduction to Project Synapse 01:12 Meet Christopher Pinard: Veterinary Oncologist 01:27 The Evolution of Veterinary Specialties 02:02 Training and Clinical Trials in Veterinary Oncology 03:21 AI in Veterinary Medicine 03:48 The Intersection of Veterinary and Human Medicine 04:34 Challenges in Veterinary Medicine 05:19 Cancer Statistics in Pets 09:12 Protein Folding and AI in Drug Development 23:48 AI Scribes and Summarization in Veterinary Medicine 35:43 Guardrails to Prevent Hallucinations 36:57 Embedding Models and Knowledge Graphs 37:49 Introducing Hero: The Rationalization Engine 38:11 Grading Methodology for AI Outputs 39:18 Using Multiple Models for Fact-Checking 43:54 Extracting Data from Clinical Records 45:45 The Future of Domain-Specific AI Models 48:16 Challenges and Opportunities in Veterinary AI 50:55 Federated Learning and Bias Mitigation 55:03 The Importance of Regulation and Education 01:01:50 Starting a Veterinary AI Business in Canada 01:08:00 Future Directions in Veterinary Oncology 01:08:58 Conclusion and Farewell

Intelligent Medicine
Leyla Weighs In on Navigating GLP-1 Medications: Addressing Side Effects and Maintaining Muscle Mass

Intelligent Medicine

Play Episode Listen Later Oct 24, 2025 24:02


Leyla Muedin, a registered dietitian nutritionist, discusses the gastrointestinal (GI) side effects commonly experienced by patients using GLP-1 medications such as Ozempic and Rybelsus. Leyla introduces a nutraceutical called Digexin, created by N-X-T-U-S-A, which has shown promise in mitigating these side effects and improving overall well-being. The episode highlights the need for patients to prioritize animal protein intake and incorporate strength training to maintain muscle mass, especially when taking GLP-1 medications. Leyla emphasizes the importance of developing healthy habits and lifestyle changes to sustain weight loss after discontinuing these drugs.

Not Another Fitness Podcast: For Fitness Geeks Only
Episode 350: From Halo to Flow: The Future of Brain Performance Tech w/ Erin Lee of Flow Neuroscience

Not Another Fitness Podcast: For Fitness Geeks Only

Play Episode Listen Later Oct 24, 2025 58:18


In this episode of the Flex Diet Podcast, I'm joined by Erin Silver Lee, the CEO of Flow Neuroscience. We dig into some seriously cool stuff — including Flow's recent acquisition of the Halo device, which uses non-invasive brain stimulation (TDCS) to boost both athletic and mental performance.Erin and I talk about how this tech works, what the current research says, and how it's being applied to improve focus, sleep, neuroplasticity, and overall brain health. We also get into the real-world side of things — from navigating FDA regulations to running clinical trials and shaping the future of personalized brain optimization.If you're curious about where neuroscience meets performance — and how safe, evidence-based brain stimulation might fit into the next generation of recovery and training tools — you'll want to check this one out.Sponsors:Beyond Power Voltra 1: https://www.beyond-power.com/michael13Tecton Ketone Esters: https://tectonketones.comAvailable now:Grab a copy of the Triphasic Training II book I co-wrote with Cal Deitz here.Episode Chapters:00:38 Background on Halo Device and Flow Neuroscience01:50 Acquisition and Technology Insights02:09 FDA Regulation and Consumer Approval06:02 New Device Focus and User Benefits07:29 Device Design and Usage08:45 Impact on Sleep and Mental Performance16:17 Personalization and Future Developments26:06 Focus and Concentration Benefits29:33 Navigating FDA Regulations30:35 Depression Treatment Success in Europe30:51 Challenges with Regulatory Approval31:50 Real-World Success and Halo Product Launch33:23 Navigating FDA Approval and Bias42:45 Clinical Trials and Expanding Indications51:25 Brain Health and Personal Practices55:33 Podcast Conclusion and Listener Information Flex Diet Podcasts You May Enjoy: Episode 346: From Navy SEAL to Neuroscience: Dr. Blaine Lints on Ibogaine and PerformanceYouTube: https://youtu.be/8UNGgyqBWm0 Episode 241: A New Perspective on Brain Health with Dr. Shaun KornfeldYouTube: https://youtu.be/1HcgPp6Wz7QConnect with Flow Neuroscience:Website: https://www.haloneuroscience.com/Facebook: https://www.facebook.com/halo.neuroscienceYouTube: https://www.youtube.com/@HaloNeuroscienceLinkedIn: https://www.linkedin.com/company/halo-neuroscience/Instagram: https://www.instagram.com/halo.neuro/Get In Touch with Dr Mike:Instagram: DrmiketnelsonYouTube: @flexdietcertEmail: Miketnelson.com/contact-us

The Future of Everything presented by Stanford Engineering

Clinician-scientist Jill Helms is an expert on healing. Until about age 30, people heal easily, she says, but later on, not so well. Regenerative medicine suggests avenues for improvement, she promises. Her research focuses on understanding the physical and molecular processes of healing to design better therapies. One approach awakens “sleeper” stem cells to aid healing, a new drug in trial regenerates bone, and another avenue targets infections that appear near medical devices using gum-like tissues that create sealing barriers. In many ways, nature remains our best model for healing, Helms tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: Jill HelmsConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Jill Helms, a professor of surgery at Stanford University.(00:03:42) Why Study Wound HealingJill shares what led her to explore how the body repairs itself after injury.(00:04:23) How Healing WorksExplanation of physical signals, stem cells, and the stages of tissue repair.(00:07:23) Healing Declines with AgeHow healing quality and speed drop significantly after age thirty.(00:10:48) Physical vs. Biological SignalsThe biological and physical signals that work together to guide healing.(00:13:21) Regenerative MedicineTherapies designed to restore healing capacity and accelerate repair.(00:16:55) Infection and ImplantsChallenges of preventing infections around skin penetrating medical devices.(00:21:54) Nature's BlueprintUsing biological models to inspire self-renewing wound interfaces.(00:26:19)  Biomimicry and Evolutionary InsightWhat scientists are learning from animals to inform human tissue repair.(00:30:51) Future In a MinuteRapid-fire Q&A: scientific curiosity, young researchers, and supportive environments.(00:33:04) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Proactive - Interviews for investors
Medicus Pharma begins phase 2 clinical trial in UAE for SkinJect skin cancer treatment

Proactive - Interviews for investors

Play Episode Listen Later Oct 23, 2025 5:01


Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major clinical milestone — the enrollment of the first patient in the company's SKNJCT-004 Phase 2 clinical trial in the United Arab Emirates (UAE). The study aims to evaluate a non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The multi-center, double-blind, placebo-controlled trial will enroll 36 patients across six leading medical institutions in the UAE, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and American Hospital of Dubai. Dr. Bokhari explained that the study will assess the efficacy and safety of two dose levels of Medicus Pharma's proprietary D-MNA (drug-coated microneedle array) compared to a placebo control. Participants will be randomized into three groups, a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The 200μg dose represents the maximum level previously used in the company's successful Phase 1 safety and tolerability trial (SKNJCT-001), completed in March 2021. Dr. Bokhari emphasized that this next phase marks a significant step forward for Medicus Pharma's mission to develop non-invasive dermatological treatments that can potentially eliminate the need for surgical excision in certain skin cancer cases. With recruitment underway and multiple top-tier hospitals participating, the SKNJCT-004 study positions Medicus Pharma at the forefront of innovative, patient-friendly oncology solutions in the Middle East and beyond. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

The MSing Link
255. CAR-T Cell Therapy for MS: Clinical Trials Now Enrolling - MS Neurologist Interview

The MSing Link

Play Episode Listen Later Oct 22, 2025 46:47


In this episode, I'm joined by Dr. Burhan Chaudhry, MS neurologist and clinical lead at Bristol Myers Squibb, to discuss CAR-T cell therapy which is an innovative treatment currently enrolling in clinical trials for multiple sclerosis (MS). We dive into how CAR-T cell therapy targets B cells within the central nervous system, offering hope for both relapsing and progressive MS. Dr. Chaudhry explains what sets CAR-T apart from traditional disease modifying therapies, how to get involved in MS clinical trials, and what participants can expect throughout the process. Whether you're newly diagnosed or living with MS for years, join us for empowering strategies, expert advice, and the latest updates on breakthroughs in MS treatment! Bio on Burhan Chaudry: Dr. Burhan Chaudhry is a MS neurologist and clinical lead at Bristol Myers Squibb. His sister was diagnosed with MS when he was in medical school. This inspired him to pursue Neurology. A few years after Burhan was diagnosed with MS as well. After becoming a MS neurologist, Burhan has treated MS patients both in the US and internationally. He is currently clinical lead for a global clinical trial evaluating a novel cell therapy across the MS spectrum. Resources mentioned in this episode: Website to view CAR-T info: https://www.cartautoimmune.com/ ECTRIMS 2025 Results/Report: https://distribute.congrex.com/from.storage?image=rqetJOF1YXChDh_STAPoNpjPhysyG76sohBKnHJhR-TsF3Mvxzx13zdmic5t9umH0 Additional Resources: https://www.doctorgretchenhawley.com/insider Reach out to Me: hello@doctorgretchenhawley.com Website: www.MSingLink.com Social: ★ Facebook: https://www.facebook.com/groups/mswellness ★ Instagram: https://www.instagram.com/doctor.gretchen ★ YouTube: https://www.youtube.com/c/doctorgretchenhawley?sub_confirmation=1 → Game Changers Course: https://www.doctorgretchenhawley.com/GameChangersCourse → Total Core Program: https://www.doctorgretchenhawley.com/TotalCoreProgram → The MSing Link: https://www.doctorgretchenhawley.com/TheMSingLink

Health Innovation Matters
The Future of Fertility and Non-Surgical Birth Control with Kathy Lee-Sepsick

Health Innovation Matters

Play Episode Listen Later Oct 22, 2025 30:06


Michael chats with Kathy Lee-Sepsick, CEO and Founder of Femasys. Together, they discuss the founding of Femasys and the products it offers, how Kathy has gone about raising capital for a women's health company despite a challenging lack of sector investment, the importance of gathering thorough safety data for regulatory approvals and commercialization, how Kathy envisions the global commercialization rollout for FemaSeed and FemBloc in the coming months, and much more. To learn more about Femasys and its products, visit Femasys.com.

OffScrip with Matthew Zachary
GenX Therapy With Sally Wolf

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 21, 2025 41:12


Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

BackTable Urology
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill

BackTable Urology

Play Episode Listen Later Oct 21, 2025 59:51


New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologists Dr. Mark Tyson from Mayo Clinic Arizona and Dr. Suzanne Merrill from Colorado Urology.---This podcast is supported by:Ferring Pharmaceuticalshttps://www.ferring.com/home-classic/people-and-families/uro-uro-oncology/bladder-cancer/---SYNPOSISThe discussion delves into the newest treatment strategies and FDA-approved therapies for non-muscle invasive bladder cancer with an emphasis on BCG-refractory patients. They highlight their approaches to sequencing therapies, the real-world applicability of these treatments, and the impact of patient factors in clinical decision-making. The panel also explores emerging trials and innovative treatment mechanisms, emphasizing the importance of personalized care in oncology.---TIMESTAMPS00:00 - Introduction05:09 - Challenges and Strategies in Treatment10:55 - Bladder Sparing Therapies21:41 - Practical Tips for Therapy Administration30:39 - Challenges and Considerations in Reinduction37:05 - Clinical Trials and Future Directions44:11 - Counseling Patients on Treatment Options57:36 - Concluding Thoughts and Future Outlook---RESOURCESCORE-008 Clinical Trial https://www.sciencedirect.com/science/article/abs/pii/S1078143924010147Legend Clinical Trial:https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.802CISTO Studyhttps://pubmed.ncbi.nlm.nih.gov/37980511/

MDS Podcast
Disease modification and Parkinson's disease: Clinical trial design and population selection • 2025 MDS Congress

MDS Podcast

Play Episode Listen Later Oct 20, 2025


There have been nearly 30 years of disease modifying trials for PD, but little success. Prof. Tanya Simuni breaks down clinical trial design for a heterogenous disease like PD and discusses the future goals and importance of a biological definition.

OffScrip with Matthew Zachary
Standard Deviation EP2: Domino Effect

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 16, 2025 10:43


Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

MedEvidence! Truth Behind the Data
Learning About the Great Unlearning (Alzheimer's)

MedEvidence! Truth Behind the Data

Play Episode Listen Later Oct 15, 2025 28:09 Transcription Available


Send us a textDr. Reza Bolouri, a memory expert, joins Dr. Michael Koren to discuss Alzheimer's, what it is, the risks, how it differs from other forms of dementia. The doctors also explore how treatment of dementia has evolved and progressed over the years from symptomatic treatments to new, disease-modifying medications that can slow the progression of Alzheimer's. They also talk about how clinical trials are exploring the next generation of Alzheimer's medications and tests which may provide preventative solutions to stop the disease before it even starts.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Health and Medicine (Video)
Translational Geroscience: Using Aging Research to Improve Resilience in Older Adults

Health and Medicine (Video)

Play Episode Listen Later Oct 15, 2025 48:00


Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Oncology Data Advisor
Additional Advances in Systemic Mastocytosis Research and Clinical Trials With Mariana Castells, MD, PhD + Module 1

Oncology Data Advisor

Play Episode Listen Later Oct 15, 2025 43:07


Stay ahead in Systemic Mastocytosis (SM) treatment! This interview, featuring Dr. Mariana Castells, explores the latest advancements in patient-centered care, including new drug approvals, multidisciplinary approaches, and crucial diagnostic updates. Learn how to shorten diagnosis times and improve long-term patient quality of life. Stay tuned after the interview to hear Module 1 of the podcast series, "Mastering Systemic Mastocytosis: From Early Detection to Tailored Treatment Strategies" Don't forget to claim your credit after the episode! Click on the link to claim your credit for module 1: bit.ly/3Y3ivHM Click here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP

University of California Audio Podcasts (Audio)
Translational Geroscience: Using Aging Research to Improve Resilience in Older Adults

University of California Audio Podcasts (Audio)

Play Episode Listen Later Oct 15, 2025 48:00


Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Health and Medicine (Audio)
Translational Geroscience: Using Aging Research to Improve Resilience in Older Adults

Health and Medicine (Audio)

Play Episode Listen Later Oct 15, 2025 48:00


Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

Aging and Senior Health (Audio)
Translational Geroscience: Using Aging Research to Improve Resilience in Older Adults

Aging and Senior Health (Audio)

Play Episode Listen Later Oct 15, 2025 48:00


Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

UC San Diego (Audio)
Translational Geroscience: Using Aging Research to Improve Resilience in Older Adults

UC San Diego (Audio)

Play Episode Listen Later Oct 15, 2025 48:00


Targeting the biology of aging offers a path to stronger resilience and longer health. John C. Newman, M.D., Ph.D., explains that aging arises from measurable cellular processes, often called hallmarks of aging, including changes involving mitochondria, stem cells, cellular senescence, inflammation, and protein quality control. Newman describes how basic science in model organisms reveals mechanisms that can be manipulated to extend healthy lifespan and guide therapies. Emerging approaches aim either to strengthen stress responses that make cells more resilient or to address downstream consequences. Many clinical studies across the country now test interventions that target aging, supported by national efforts to standardize methods and expand training. Newman also investigates ketone bodies as energy sources that influence inflammation, muscle preservation, and other processes relevant to frailty and recovery. Series: "Stein Institute for Research on Aging" [Health and Medicine] [Show ID: 40961]

OffScrip with Matthew Zachary
Family Reach: The Charity America Forced Into Existence

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 14, 2025 40:59


Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Empowered Patient Podcast
AI Agent Automates Clinical Trial Recruitment Fast Tracking Drug Development with Trân Lê Grove AI

Empowered Patient Podcast

Play Episode Listen Later Oct 14, 2025 19:06


Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients."   "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment."   "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Download the transcript here

Empowered Patient Podcast
AI Agent Automates Clinical Trial Recruitment Fast Tracking Drug Development with Trân Lê Grove AI TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Oct 14, 2025


Trân Lê, Co-Founder and CEO of Grove AI,  was founded to automate the manual and inefficient workflows in clinical trial recruitment, patient engagement, and support. The company's AI agent, Grace, is trained on specific trial protocols and approved scripts to respond to patient questions about pre-screening, logistics, and scheduling appointments. This platform aims to increase speed and quality of participant recruitment, improve representation, and expand accessibility to clinical trials by offering support in over 19 languages and providing access to information on demand. Trân explains, "The birth of Grove really came from my co-founder, Sohit, and his experience working in the hospital. We were working at Stanford, and there we were, computer scientists building a lot of internal tools for clinical trials, clinical research, as well as for the greater healthcare patient services. And that, combined with my experience trying to enroll in a clinical trial, really set us off to think deeply about how we can automate a lot of the manual workflows that exist today for patients and for providers, as well as for pharma in taking new drugs to market. Specifically, within that, we identified patient engagement and support, and prescreening to be an important part of ensuring that patients know where they're going and what to do when they're participating in these trials. And so we decided to really step out into the industry and change this process and make it an easier and more accessible experience for patients."   "I would say that having worked inside a hospital and seeing all of this lead generation or getting people educated about the trial is an important aspect, and it's being done by a lot of the recruitment vendors as well as in-house teams out there. In addition to that, a bottleneck that previously has always been there now is possible to automate with agentic AI is actually doing the work of taking all the interest from different potential patients and helping them prescreen and understand the requirements of the trials, getting them to the right site, booking their transportation, reminding them about the appointments, and scheduling that appointment."   "I would say that Grace, as we call her, is a digital staff or an AI agent - both are comparable terms to describe Grace. The difference is that Grace is trained on the trial, the requirements, and the IRB-approved script of that trial. So she really has the knowledge to be able to respond spontaneously in real time to any questions that the participant may have about the trial." #GroveAI #ClinicalTrials #PatientRecruitment #Pharma #HealthTech #DigitalHealth #AI #AgenticAI grovetrials.com Listen to the podcast here

JACC Speciality Journals
Brief Introduction - The Asia Pacific Cardiovascular Research (ASPIRE) Network: Facilitating and Advancing Regional Cardiovascular Clinical Trials | JACC: Asia

JACC Speciality Journals

Play Episode Listen Later Oct 14, 2025 2:24


RealTalk MS
Episode 424: I'm a Participant in a Clinical Trial for CAR-T Cell Therapy and MS with Jan Janisch-Hanzlik

RealTalk MS

Play Episode Listen Later Oct 13, 2025 33:05


Jan Janisch-Hanzlik lives with MS and is a participant in one of the clinical trials evaluating the safety and efficacy of CAR-T cell therapy for MS. Jan is the first person in the world to receive this one-and-done treatment, and this week, she's joining me to share her experience participating in the clinical trial. But you'll be especially interested in hearing how CAR-T cell therapy has impacted Jan's MS. Open enrollment for people with Medicare and for those who get their health insurance through the ACA healthcare.gov Marketplace begins this week, and we're talking about some of the reasons you want to pay particular attention to your 2026 health insurance options. As the U.S. federal government shutdown enters its third week, we're reviewing some of the ways that the shutdown may affect someone living with MS. And we're giving you a reminder about how you can add your voice and share your story of living with MS with the FDA by participating in the Shaping Tomorrow Together initiative. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: A first-hand account of an important clinical trial, open enrollment begins, and how the government shutdown may affect people with MS  :22 Open enrollment for Medicare and Marketplace enrolees begins  :22 How the federal government shutdown could affect people living with MS  4:29 Your opportunity to tell the FDA what it's like to live with MS  8:57 Jan Janisch-Hanzlik shares her experience participating in a CAR-T cell therapy clinical trial, and how the treatment has impacted her MS  11:28 Share this episode  31:38 Next week's episode  31:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/424 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com PARTICIPATE: Take the Shaping Tomorrow Together Survey https://s.alchemer.com/s3/Perspectives-on-MS REGISTER: Attend the virtual Shaping Tomorrow Together meeting with the FDA https://nmss.quorum.us/event/25463 SIGN UP: Become an MS Activist https://nationalmssociety.org/advocacy JOIN: The RealTalk MS Facebook Group https://facebook.com/groups/realtalkms DOWNLOAD: The RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 DOWNLOAD: The RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk REVIEW: Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 424 Guest: Jan Janisch-Hanzlik Privacy Policy

Intelligent Medicine
Intelligent Medicine Radio for October 11, Part 2: Psychological Benefits from Grandparent Time

Intelligent Medicine

Play Episode Listen Later Oct 13, 2025 44:14


Examining the claim that cabbage family vegetables are bad for the thyroid; Walmart announces sweeping move to reformulate its products without synthetic dyes, sketchy additives; Under Congressional questioning, Google admits to censoring contrary narratives on YouTube during Covid; Children garner psychological benefits from grandparent time; J&J fined nearly $1 billion in landmark talc baby powder lawsuit; Humans are among the few animals who can't make their own vitamin C—why that may be a good thing.

Let's Talk About Your Breasts
The Importance of Clinical Trials for Breast Cancer Patients

Let's Talk About Your Breasts

Play Episode Listen Later Oct 13, 2025 35:00


Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Elkhanany breaks down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Let's Talk About Your Breasts
The Importance of Clinical Trials for Breast Cancer Patients

Let's Talk About Your Breasts

Play Episode Listen Later Oct 13, 2025 35:00


Clinical trials pave the way for new breast cancer treatments, but many patients hesitate to take part. Dr. Ahmed Elkhanany returns to the show to break down what these studies really mean and why access and education make a difference. What clinical trials are and how they work for patients Why every standard medicine starts with a trial How learning and access change treatment for everyone Key Questions Answered What is a clinical trial? Why do we need clinical trials? How do clinical trials progress from phase one to phase four? Why is it often difficult to get people to participate in clinical trials? How do you address patient skepticism towards clinical trials? Who decides if a new drug’s benefit is worth its risks? How do drug approval processes in the United States differ from those in Europe? What are the potential benefits for patients who participate in clinical trials? How do you approach a patient when recommending a clinical trial, especially if standard treatments have failed? What support systems exist to help patients participate in clinical trials, especially those traveling long distances or facing financial barriers? Timestamped Overview 00:00 Understanding Clinical Trials Stages 06:10 Advancing Medicine Through Clinical Trials 07:49 Cancer Treatment Decision Challenges 12:03 Global Drug Trial Decision Process 16:31 Immunotherapy Breakthrough in Cancer Treatment 20:10 Clinical Trials: Challenges and Importance 23:52 Key Patient Advice: Second Opinions 26:01 Bridging Clinical Trial Accessibility 29:05 Advancements Reducing Breast Cancer Mortality Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Tick Boot Camp
Episode 539: Geoff Dow on Babesiosis: Malaria Parallels, Tafenoquine (Arakoda), and New Clinical Trials for Chronic Tick-Borne Disease

Tick Boot Camp

Play Episode Listen Later Oct 11, 2025 80:02


Dr. Geoff Dow, CEO of 60 Degrees Pharmaceuticals and former malaria drug developer at Walter Reed, joins the Tick Boot Camp Podcast to unpack the science and strategy behind treating babesiosis. Drawing parallels to malaria, Dow explains why tafenoquine (brand: Arakoda), FDA-approved for malaria prevention, is being studied for Babesia, how coinfections (Borrelia, Bartonella) complicate care, and why chronic illness needs a different clinical approach. He previews an upcoming Mount Sinai trial for chronic babesiosis focused on fatigue outcomes and discusses real-world diagnostics using FDA-approved blood donor screening plus PCRs from Galaxy Diagnostics and Mayo Clinic. The conversation also touches on prophylaxis concepts, immune dysregulation, and building a clearer path from anecdote to evidence for the tick-borne disease community. Guest Geoff Dow, BSc, MBA, PhD CEO & Board Member, 60 Degrees Pharmaceuticals Background: Biotechnology (Perth, Australia), PhD in malaria drug discovery, decade at Walter Reed Army Institute of Research, MBA in the U.S. Leads clinical programs exploring tafenoquine for babesiosis. Key Topics & Takeaways Malaria ↔ Babesiosis Parallels: Both are red-blood-cell parasites; acute symptoms driven by red cell destruction. Similar drug targets justify testing some anti-malarials against Babesia. Why Tafenoquine (Arakoda): An 8-aminoquinoline that induces oxidative stress in RBCs; distinct mechanism from atovaquone + azithromycin combo (current standard for acute babesiosis), potentially useful for resistance management. Chronic vs. Acute Disease: Acute babesiosis in immunocompetent patients often responds to standard care; chronic illness remains under-defined and underserved. Coinfections Are Common: Many chronically ill patients present with Borrelia, Bartonella, and Babesia together; diagnostics and treatment need to acknowledge polymicrobial reality. Upcoming Clinical Trial (Mount Sinai): Population: Chronic babesiosis with disabling fatigue, plus Babesia symptoms (e.g., air hunger, anemia) and lab evidence in the last 12 months. Regimen: 4-day loading dose then 200 mg weekly of tafenoquine for 3 months. Outcomes: Patient-reported fatigue (quality-of-life) + monthly molecular testing (FDA blood donor test, Galaxy Diagnostics PCR, Mayo Clinic PCR) during treatment and 3 months post-therapy. Goals: Demonstrate symptom improvement, assess eradication signals, and validate accessible diagnostics against an FDA-accepted assay. Prophylaxis & Post-Exposure Ideas: Animal data suggest short-course tafenoquine can eradicate early Babesia; human prophylaxis trials face feasibility and regulatory hurdles. Diagnostics Gap: Need for standardized, sensitive tools to define chronic babesiosis and track response. This trial also serves as a real-world diagnostic comparison. Immune Dysregulation & IACI: Overlap among long COVID, ME/CFS, post-treatment Lyme—shared theme of immune dysregulation with possible persistent antigen stimulation. Safety Notes: G6PD deficiency is relevant to 8-aminoquinolines; established safety database exists for malaria prevention dosing—critical as studies expand to babesiosis. Notable Quotes “You've got to put some lines in the sand—run the trial, collect data, and move the field forward.” “The best we can do for chronic disease starts with defining it—and validating the diagnostics we use to track it.” “8-aminoquinolines offer a different mechanism than current babesiosis standards—key for resistance and combinations.” Resources Mentioned Arakoda (tafenoquine): FDA-approved for malaria prevention; under study for babesiosis. Diagnostics: FDA-approved Babesia blood donor screen; Galaxy Diagnostics PCR; Mayo Clinic PCR. Organizations & Events: ILADS, Global Lyme Alliance, tick-borne disease conferences. Research Partners: Mount Sinai (NYC), Tulane University (Bartonella/Borrelia collaboration). Who Should Listen Patients with chronic Lyme or chronic babesiosis symptoms (fatigue, air hunger, anemia) Clinicians seeking updates on Babesia treatment research and diagnostics Caregivers and advocates tracking IACI and immune dysregulation science Researchers exploring antimalarial repurposing for tick-borne diseases Call to Action Subscribe to Tick Boot Camp and share this episode with someone navigating chronic tick-borne illness.

Science (Video)
Stem Cells and Precision Regenerative Medicine in Breast Cancer - Medicine Informing Novel Discoveries (MIND)

Science (Video)

Play Episode Listen Later Oct 11, 2025 67:39


Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Health and Medicine (Video)
Stem Cells and Precision Regenerative Medicine in Breast Cancer - Medicine Informing Novel Discoveries (MIND)

Health and Medicine (Video)

Play Episode Listen Later Oct 11, 2025 67:39


Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

University of California Audio Podcasts (Audio)
Stem Cells and Precision Regenerative Medicine in Breast Cancer - Medicine Informing Novel Discoveries (MIND)

University of California Audio Podcasts (Audio)

Play Episode Listen Later Oct 11, 2025 67:39


Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

Health and Medicine (Audio)
Stem Cells and Precision Regenerative Medicine in Breast Cancer - Medicine Informing Novel Discoveries (MIND)

Health and Medicine (Audio)

Play Episode Listen Later Oct 11, 2025 67:39


Advances in precision medicine and patient advocacy are transforming the way cancer is understood and treated. Nikoo McGoldrick shares her personal journey with metastatic breast cancer, emphasizing the importance of patients having a voice in their care. Sheldon Morris, M.D., M.P.H., explains how regenerative medicine progresses through stem cell therapies, gene therapies, CAR-T cell treatments, and small molecules, with clinical trials addressing cancer, autoimmune disorders, and neurological diseases. Sandip Patel, M.D., F.A.S.C.O., highlights cancer stem cells as key drivers of relapse and resistance, describing precision medicine approaches, novel CAR-T therapies, and the role of artificial intelligence in cancer detection and treatment. Rebecca Shatsky, M.D., focuses on breast cancer as a systemic disease linked to dormant cancer stem cells, underscoring the need for genomic and immune-based therapies, including innovative antibody treatments and targeted clinical trials. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40910]

RealTalk MS
Special Episode: The Risks and Rewards of Participating in Clinical Trials with Dr. Kathy Zackowski and Mimi Brown

RealTalk MS

Play Episode Listen Later Oct 10, 2025 21:04


Welcome to a RealTalk MS special series on MS clinical trials. This special series is made possible through a generous grant from Sanofi.   In today's episode, we're exploring the risks and rewards of participating in a clinical trial with Dr. Kathy Zackowski and Mimi Brown.  Dr. Zackowski is the Associate Vice President of Research at the National MS Society, and she's going to offer an overview of the risks and benefits that you'll want to weigh in considering participating in a clinical trial. Mimi Brown lives with primary progressive MS, and Mimi is going to share her own experience as a participant in multiple clinical trials.    This special episode of RealTalk MS has been made possible through a generous grant from Sanofi. Sanofi has two ongoing Phase 3 clinical trials in MS studying Frexalimab, an investigational second-generation anti-CD40 ligand monoclonal antibody. If you are interested in learning more about these clinical trials, please visit SanofiStudies.com SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/ct2 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! Privacy Policy

MedEvidence! Truth Behind the Data
What Makes for a Good Doctor? Part 2

MedEvidence! Truth Behind the Data

Play Episode Listen Later Oct 10, 2025 25:23 Transcription Available


Send us a textDr. David Joseph rejoins Dr. Michael Koren for part 2 of his journey from reluctant med student to medical consultant, inventor, and artist. In this section, Dr. Joseph talks about the difficulties in navigating our current, disjointed, and often impersonal medical system. He recounts having to go through seven different consultations with physicians before anyone physically examined him and how persistence is key in our medical system. They finish up by talking about the doctor's artwork, which can be found at https://www.davidjosephart.com/ and on Instagram at @artbydavidjosephBe a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

Inside Biotech
The Future of Mental Health Treatment with Shawn Singh, CEO of Vistagen

Inside Biotech

Play Episode Listen Later Oct 10, 2025 51:57


CEO of Vistagen, Shawn Singh, returns to Inside Biotech to discuss groundbreaking developments in intranasal therapeutics. Shawn shares exciting results from Vistagen's fast-track phase 3 trials, explains how intranasal drug delivery bypasses limitations of traditional therapeutics relying on systemic absorption, and reflects on telehealth's role in accessibility. This conversation spotlights a transformative moment in neuroscience, drug development and mental health innovation.Learn more about Vistagen: https://www.vistagen.com/Listen to our previous episode with Shawn to learn more about social anxiety disorder and the earlier days of Vistagen: https://inside-biotech.simplecast.com/episodes/shawn-singh-ceo-of-vistagen-mental-health-biopharmaceuticals Follow our Instagram @insidebiotech for updates about episodes and upcoming guests!To learn more about BCLA's events and consulting visit our website.Follow BCLA on LinkedIn

10 Minutes to Better Patient Communication
Lakshmi Grama on how people affected by cancer helped shape Cancer.gov’s Clinical Trials Information (Part 2)

10 Minutes to Better Patient Communication

Play Episode Listen Later Oct 10, 2025 12:26


In Part 2 of my interview with Lakshmi Grama, we find out what happened when the NCI team involved people affected by cancer in naming a new part of the cancer.gov website. Lakshmi also reveals how NCI was already exploring the possibilities of generative AI for precision communication about cancer. Missed Part 1 of our […] The post Lakshmi Grama on how people affected by cancer helped shape Cancer.gov’s Clinical Trials Information (Part 2) appeared first on Health Communication Partners.

SurgOnc Today
SSO Education Series: Hispanic Heritage Month: Innovative Clinical Trial Recruitment

SurgOnc Today

Play Episode Listen Later Oct 9, 2025 29:47


On this episode of SurgOnc today, Dr. Rosalinda Alvarado and Dr. George Molina moderate a discussion on how to improve the recruitment of Hispanic/Latino patients into clinical trials. Joining the conversation are Jeanette Gonzalez from the University of Illinois Cancer Center and Alas-Wings, Dr. Narjust Florez from Dana-Farber Cancer Institute and Harvard Medical School, and Dr. Kennedy Timothy from MedStar Health and Georgetown University.

Empowered Patient Podcast
AI Platform Expands Clinical Trial Recruitment and Diversity with Kourosh Davarpanah Inato

Empowered Patient Podcast

Play Episode Listen Later Oct 9, 2025 19:22


Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials.   Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating."   "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment  Inato.com Download the transcript here

Empowered Patient Podcast
AI Platform Expands Clinical Trial Recruitment and Diversity with Kourosh Davarpanah Inato TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Oct 9, 2025


Kourosh Davarpanah, Co-Founder and CEO of Inato, is using an AI-enabled platform to transform participation in clinical trials. The existing clinical trial system is not seen as representative of the general population, and FDA directives have addressed this lack of diversity. The Inato platform features a marketplace approach that connects trial sponsors with a broader range of hospital sites, as well as an AI tool to assist doctors in identifying patients who are eligible for trials.   Kourosh explains, "Our focus at Inato is to expand the number of patients who are able to participate in clinical research. If you think about how things have been done for the past decades, most of the patients who have the opportunity to participate are coming from the larger academic hospitals. And what this means is that typically, 5% of the sites, meaning 5% of the hospitals running research, run about 70% of all the trials globally. So this has an impact not only on the number of patients that can actually participate in trials, but it also has an impact on the type of patients. So, typically, those are going to be white patients, richer patients. And so it has a big impact also on equity and on the diversity--and ethnic diversity especially--of patients participating."   "We have two pieces of the platform. The first piece is that we're helping connect the hospitals running the trials with trials that are being run by the sponsors. So the way this works is similar to marketplaces like Airbnb, where you have the sponsor that can share any number of upcoming trials. We enable the sites to discover all the trials on the platform and showcase, based on their profiles, how many trials they have done in the past, what is the makeup of the team and doctors, etc. We're able to allow them to get selected in trials that they otherwise wouldn't be able to get selected for. So this is the first piece of it, really connecting the sites and the trials. And increasingly with AI, we've started supporting sites in actually identifying patients at scale. And this has really been a massive tech shift, where the latest generations of LLMs are able to accurately identify patients eligible for any trial with over 95% accuracy." #Inato #ClinicalTrials #ClinicalRearch #AI #MedAI #DrugDevelopment  Inato.com Listen to the podcast here

Longevity by Design
Building a Blueprint for Longer Lives Through Public Policy

Longevity by Design

Play Episode Listen Later Oct 8, 2025 59:33


In this episode of Longevity by Design, our host, Dr. Gil Blander, sits down with Dylan Livingston, CEO at the Alliance for Longevity Initiatives, and Dr. Brenda Eap to explore how public policy shapes the future of aging research. Dylan and Brendan share how their team pushes for legislation that supports healthy lifespan extension, aiming to bring longevity science into the center of national health priorities.Dylan and Brendan explain why policy advocacy is crucial for securing funding for research, reducing regulatory hurdles, and establishing a clear path for new therapies. They outline recent successes, including building bipartisan support in Congress and expanding access to experimental treatments in states such as Montana. Throughout their discussion, Dylan shows how effective communication,  using stories and simple analogies, helps move longevity from the lab to lawmakers' agendas.The episode closes with practical advice for listeners. Dylan highlights the power of community, clear communication, and grassroots action as tools that help turn advanced science into real-world health gains.Episode highlights:[00:00:00]: Introduction[00:01:00]: Overview of Longevity Policy and Research Funding[00:02:00]: Backgrounds and Personal Journeys into Longevity Advocacy[00:05:00]: Inspiration and Founding of Longevity Policy Organization[00:07:00]: Scientific Training and Motivation for Policy Work[00:09:00]: Mission and Approach of Longevity Advocacy Organization[00:10:00]: Policy Advocacy's Role in Advancing Longevity Research[00:12:00]: Gaps in Funding and the Importance of Government Engagement[00:13:00]: Experiences with Policy Events and Realizations about Advocacy[00:14:00]: Early Accomplishments and Congressional Engagement[00:15:00]: Building Bipartisan Support and the Longevity Science Caucus[00:16:00]: Legislative Engagement and Policy Paper Development[00:17:00]: State-Level Policy Wins and Expansion of Right to Try Laws[00:19:00]: Rationale and Strategy for State-Level Focus[00:21:00]: Plans for Geographic Expansion of Longevity Policy Initiatives[00:23:00]: Political Climate and Opportunities with the Current Administration[00:25:00]: Shifts in Federal Attitudes Toward Longevity and Healthspan[00:27:00]: Demographics, Policy Momentum, and National Health Priorities[00:29:00]: Prevention Versus Treatment: Shifting Policy Mindsets[00:32:00]: Communicating Policy Opportunities to a Wider Audience[00:34:00]: Ensuring Longevity Policy Remains Bipartisan[00:35:00]: Intersection of Policy, Science, and Public Engagement[00:37:00]: Funding and Regulatory Challenges in Longevity Research[00:39:00]: Barriers in Clinical Trials and Policy Modernization[00:40:00]: Strategies for Communicating Longevity Science to Policymakers[00:44:00]: Framing Longevity for Policy Impact and Public Understanding[00:48:00]: Future Vision and Milestones for Longevity Policy[00:51:00]: How Individuals and Organizations Can Support Longevity Advocacy[00:55:00]: Practical Longevity Advice and Episode ConclusionWe Appreciate You!As a token of our gratitude, we're excited to offer you 15% off your next purchase. Simply click the link below to redeem your discount: https://info.insidetracker.com/podcastFor science-backed ways to live a healthier, longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast

The Sacred Purpose Podcast
48. Transforming Healthcare Communication and Patient Engagement With Kavita Bouknight

The Sacred Purpose Podcast

Play Episode Listen Later Oct 8, 2025 41:38 Transcription Available


If you've ever felt alone in the healthcare maze, this episode is here to remind you: your story matters, and you are not alone. Kavita Bouknight shares how her personal health journey and family experiences inspired her mission to make healthcare information more accessible, and how she's leveraging technology through her company's program, SPARK, to bridge crucial communication gaps between patients and providers. The conversation explores the needs and future of women's health, the entrepreneurial path, and the importance of advocating for yourself and others in today's complex medical landscape.    TIMESTAMPS: 00:00 "Match Health Collective Founder Interview" 03:40 "Navigating Care in Sandwich Generation" 08:01 Navigating Stressful Situations 10:10 Navigating Healthcare Isolation 16:01 Patient Engagement in Clinical Trials 19:48 Advocating for Clear Breast Health 22:17 Dense Breast Tissue Awareness 25:49 Take the Leap and Evolve 27:18 Entrepreneurial Evolution and Vision 29:51 Naming Expertise Transforms Business 34:06 Boosting Women's Health Awareness 38:21 Feeling Alone Despite Support 39:39 Expressing Gratitude and Support   LEARN MORE: The Clear Pathways Program: https://www.breastdensitysummit.org/ MAKE A DONATION: https://www.paypal.com/donate?hosted_button_id=NJMF86A8Y9RJQ Women's Health Advocates: https://womenshealthadvocates.org/   With a focus on health innovation and high-impact marketing, Kavita Bouknight is a trusted advisor to venture-backed startups and publicly traded healthcare organizations, bringing over 20 years of experience in strategy and go-to-market execution. She is the Founder and CEO of Match Health Collective, a full-service marketing agency that helps medical device and life science companies build brands, accelerate clinical adoption, and engage patients and physicians. She also leads Match Health Academy, which develops programs and tools to drive meaningful engagement and make complex health information more accessible through video and text-based communication. FOLLOW KAVITA:  Website: https://matchhealth.com Kavita LinkedIn: https://linkedin.com/in/kavitabouknight/ Match Health Collective LinkedIn: https://www.linkedin.com/company/match-health-collective/?viewAsMember=true   FOLLOW LISA: https://www.linkedin.com/in/lisamalianorman/ https://www.instagram.com/lisamalia.evoke/  

MedEvidence! Truth Behind the Data
What Makes for a Good Doctor?

MedEvidence! Truth Behind the Data

Play Episode Listen Later Oct 8, 2025 30:37 Transcription Available


Send us a textDr. David Joseph joins Dr. Michael Koren in part 1 of this 2-part series to discuss his journey into the medical world - with myriad tangents and diversions along the way. Dr. Joseph explores his journey from scrappy teen entrepreneur and freshman MIT researcher and inventor to Harvard-trained anesthesiologist. He talks about his non-standard approach to applying to and studying at Harvard Medical School and how his nontraditional approach to life has led him to interesting places.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

OffScrip with Matthew Zachary
The Genes of Wrath: Jennifer J. Brown

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 7, 2025 40:46


Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dementia Matters
Clarifying the Alzheimer's Disease Clinical Trials Landscape

Dementia Matters

Play Episode Listen Later Oct 7, 2025 29:52


Clinical trials are essential for improving the lives of those diagnosed with Alzheimer's disease and related dementias. With so many trials out there, it can be difficult for someone who's interested in participating in research to know where to start. Dr. Jonathan Graff-Radford joins the podcast to discuss the ins and outs of clinical trials and the state of Alzheimer's treatments today, as well as share some highlights from his presentation at the National Alzheimer's Coordinating Center's (NACC) 2025 Spring ADRC Meeting. Guest: Jonathan Graff-Radford, MD, behavioral neurologist, associate professor, vice chair, Mayo Clinic Department of Neurology, co-investigator, Mayo Clinic Alzheimer's Disease Research Center Show Notes Read more about Dr. Jonathan Graff-Radford at his profile on Mayo Clinic's website. Listen to part one and part two of our series on preclinical Alzheimer's disease and the AHEAD study with Dr. Reisa Sperling, mentioned at 19:53, on our website. Learn more about the AHEAD study on their website. Learn more about clinical trials in Wisconsin at the UW Clinical Trials Institute's website. Interested in participating in clinical trials? Visit clinicaltrials.gov or Alzheimer's Association's TrialMatch to learn how to get involved. Learn more and register for the 2025 Fall Community Conversation: Addressing Hearing Loss for Better Brain Health on our website. Connect with us Find transcripts and more at our website. Email Dementia Matters: dementiamatters@medicine.wisc.edu Follow us on Facebook and Twitter. Subscribe to the Wisconsin Alzheimer's Disease Research Center's e-newsletter. Enjoy Dementia Matters? Consider making a gift to the Dementia Matters fund through the UW Initiative to End Alzheimer's. All donations go toward outreach and production.

Sarc Fighter: Living with Sarcoidosis and other rare diseases
Episode 148 | FMLA Clarifiction Part 2 - A real life story of the perils of trying to stay in a clinical trial and how FSR achieved the FMLA Clarification

Sarc Fighter: Living with Sarcoidosis and other rare diseases

Play Episode Listen Later Oct 6, 2025 53:55


It's not always easy to participate in a clinical trial.  Even if you want to, how do you get the time off from work?  Starting in 2025, thanks to the Foundation for Sarcoidosis Research, there is a provision called the FMLA Clarification, which essentially states that you can participate without fear of losing your job.  In this episode of the FSR Sarc Fighter Podcast, Dr. Ennis James, a sarcoidosis researcher and physician at the Medical University of South Carolina, and Tricha Shivas, Chief of Staff and Strategy at FSR join me to talk about how difficult life can be for patients.  Dr. James shares a real-life story about a woman who fought to stay in a trial after problems arose at work.   SHOW NOTES OP-ED by Dr. Ennis James in STAT: https://www.statnews.com/2025/09/24/clinical-trial-patient-fmla-foundation-sarcoidosis-research-job-security/ SHRM: https://www.shrm.org/ FSR News Release: https://www.stopsarcoidosis.org/coalition-to-transform-clinical-trial-engagement-launches-champions-for-change-pto-initiative/ More from FSR: https://www.stopsarcoidosis.org/fsr-receives-confirmation-from-the-department-of-labor-ensuring-patient-access-to-fmla-for-participation-in-clinical-trials/ MORE FROM JOHN: Cycling with Sarcoidosis http://carlinthecyclist.com/category/cycling-with-sarcoidosis/ Do you like the official song for the Sarc Fighter podcast?  It's also an FSR fundraiser! If you would like to donate in honor of Mark Steier and the song, Zombie, Here is a link to his KISS account.  (Kick In to Stop Sarcoidosis)  100-percent of the money goes to the Foundation.  https://stopsarcoidosis.rallybound.org/MarkSteier The Foundation for Sarcoidosis Research https://www.stopsarcoidosis.org/ Donate to my KISS (Kick In to Stop Sarcoidosis) fund for FSR  https://stopsarcoidosis.rallybound.org/JohnCarlinVsSarcoidosis?fbclid=IwAR1g2ap1i1NCp6bQOYEFwOELdNEeclFmmLLcQQOQX_Awub1oe9bcEjK9P1E My story on Television https://www.stopsarcoidosis.org/news-anchor-sarcoidosis/ email me  carlinagency@gmail.com #sarcoidosis #sarcoidosisawareness #fmla #fmlaclarification                    

The Eye Believe Podcast
Nick's Journey: Hope Through a Clinical Trial

The Eye Believe Podcast

Play Episode Listen Later Oct 6, 2025 33:25 Transcription Available


In this compelling episode of the Eye Believe Podcast

MedEvidence! Truth Behind the Data
Unpacking what Positive Headline Results Mean in a Repatha Study

MedEvidence! Truth Behind the Data

Play Episode Listen Later Oct 6, 2025 6:37 Transcription Available


Send us a textDr. Michael Koren joins Kevin Geddings to discuss the positive headline results from a clinical study on the cholesterol medication Repatha. Dr. Koren explains what "headline results" are and how they differ from results presented in a full scientific format. He talks about how these findings are being released due to market regulations to keep the parent company of Repatha, Amgen, from violating financial laws. Dr. Koren also explains that these results are encouraging for people with high cholesterol. The study was using Repatha as a potential preventative medication and preliminary results are looking good!Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

OffScrip with Matthew Zachary
Introducing Standard Deviation EP1: The Impossible Climb

OffScrip with Matthew Zachary

Play Episode Listen Later Oct 2, 2025 9:33


This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

OffScrip with Matthew Zachary
Sorry, Your Awareness Campaign is Showing

OffScrip with Matthew Zachary

Play Episode Listen Later Sep 30, 2025 43:22


Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.